Cargando…
2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial
BACKGROUND: Antibiotic resistance in pediatrics, including neonates and infants, is increasing globally. Ceftazidime-avibactam (CAZ-AVI) is approved for use in pediatric patients (age ≥ 3 months) with Gram-negative bacterial infections. This study evaluated pharmacokinetics (PK), safety, and efficac...
Autores principales: | Bradley, John S, Roilides, Emmanuel, England, Richard, Tawadrous, Margaret, Yan, Jean, Soto, Elena, Stone, Gregory, Kamat, Shweta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678973/ http://dx.doi.org/10.1093/ofid/ofad500.2473 |
Ejemplares similares
-
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
por: Daikos, George L., et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Matesanz, Mayra, et al.
Publicado: (2021) -
Ceftazidime-avibactam
por: Herrero, Francisco Sanz
Publicado: (2022) -
Neonatal Bloodstream Infection with Ceftazidime-Avibactam-Resistant bla(KPC-2)-Producing Klebsiella pneumoniae Carrying bla(VEB-25)
por: Zarras, Charalampos, et al.
Publicado: (2023) -
Ceftazidime/avibactam for specified infections
Publicado: (2020)